{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:46Z","timestamp":1779527386239,"version":"3.53.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00841-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:02:09Z","timestamp":1774468929000},"page":"701-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns in Hospitalized Hip Fracture Patients: An Interrupted Time-Series Analysis Around the New Fee for Secondary Fracture Prevention in Japan"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-5266","authenticated-orcid":false,"given":"Saeko","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-1095","authenticated-orcid":false,"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-2747","authenticated-orcid":false,"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-6983","authenticated-orcid":false,"given":"Takeshi","family":"Sawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1480-0881","authenticated-orcid":false,"given":"Akiho","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-4364","authenticated-orcid":false,"given":"Izumi","family":"Mishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Timoshanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"9319","key":"841_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761\u20137.","journal-title":"Lancet"},{"issue":"10","key":"841_CR2","first-page":"1236","volume":"68","author":"KE Ensrud","year":"2013","unstructured":"Ensrud KE. Epidemiology of fracture risk with advancing age. J Gerontol Ser A Biomed Sci Med Sci. 2013;68(10):1236\u201342.","journal-title":"J Gerontol Ser A Biomed Sci Med Sci"},{"issue":"3","key":"841_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.injury.2007.08.014","volume":"38","author":"MJ Silva","year":"2007","unstructured":"Silva MJ. Biomechanics of osteoporotic fractures. Injury. 2007;38(3):69\u201376.","journal-title":"Injury"},{"key":"841_CR4","unstructured":"National Institute of Population and Social Security Research. https:\/\/www.ipss.go.jp\/pp-zenkoku\/j\/zenkoku2023\/pp_zenkoku2023.asp. Accessed 18 Dec 2025."},{"issue":"2","key":"841_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10428","volume":"5","author":"E Takusari","year":"2021","unstructured":"Takusari E, Sakata K, Hashimoto T, Fukushima Y, Nakamura T, Orimo H. Trends in hip fracture incidence in Japan: estimates based on nationwide hip fracture surveys from 1992 to 2017. JBMR Plus. 2021;5(2):e10428.","journal-title":"JBMR Plus"},{"issue":"10","key":"841_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/jbmr.1698","volume":"27","author":"JA Eisman","year":"2012","unstructured":"Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27(10):2039\u201346.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"841_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cger.2014.01.001","volume":"30","author":"SM Friedman","year":"2014","unstructured":"Friedman SM, Mendelson DA. Epidemiology of fragility fractures. Clin Geriatr Med. 2014;30(2):175\u201381.","journal-title":"Clin Geriatr Med"},{"key":"841_CR8","unstructured":"\u00c5kesson K, Mitchell P. Capture the fracture: a global campaign to break the fragility fracture cycle. International Osteoporosis Foundation (IOF); 2012. http:\/\/share.iofbonehealth.org\/WOD\/2012\/report\/WOD12-Report.pdf. Accessed 18 Dec 2025."},{"key":"841_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28:775\u201380.","journal-title":"Osteoporos Int"},{"key":"841_CR10","doi-asserted-by":"crossref","unstructured":"Hagino H, Yoshinaga Y, Hamaya E, Lin TC, Ajmera M, Meyers J. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database. Arch Osteopor. 2023;23;18(1):23.","DOI":"10.1007\/s11657-022-01201-x"},{"key":"841_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07687-8","author":"M Tsukamoto","year":"2025","unstructured":"Tsukamoto M, Hamasaki T, Okimoto N, Fujiwara S. Effectiveness of treatment initiation for secondary fracture prevention in the older population: Japanese Bone-fracture Osteoporosis in Late-stage population Database study (J-BOLD) \u2013 emulation of a randomized target trial. Osteoporos Int. 2025. https:\/\/doi.org\/10.1007\/s00198-025-07687-8.","journal-title":"Osteoporos Int"},{"issue":"5","key":"841_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jbmr.3953","volume":"35","author":"E Toth","year":"2020","unstructured":"Toth E, Banefelt J, \u00c5kesson K, Sp\u00e5ngeus A, Orts\u00e4ter G, Libanati C. History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90\u00a0years presenting with a fragility fracture. J Bone Miner Res. 2020;35(5):861\u20138.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"841_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00198-022-06472-1","volume":"33","author":"S Fujiwara","year":"2022","unstructured":"Fujiwara S, Buchanan-Hughes A, Ng A, Page J, Adachi K, Li H. Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database. Osteoporos Int. 2022;33(10):2205\u201316.","journal-title":"Osteoporos Int"},{"key":"841_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1007\/s00198-003-1507-z","volume":"14","author":"AR McLellan","year":"2003","unstructured":"McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003;14:1028\u201334.","journal-title":"Osteoporos Int"},{"issue":"6","key":"841_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2024.111452","volume":"55","author":"N Yamamoto","year":"2024","unstructured":"Yamamoto N, Sawaguchi T, Matsushita T, et al. Fragility fracture network-Japan: the challenge of establishment of a national hip fracture database and successful achievement of nationwide health system change for hip fracture care in Japan. Injury. 2024;55(6):111452.","journal-title":"Injury"},{"issue":"5","key":"841_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1507\/endocrj.EJ23-0040","volume":"70","author":"A Suzuki","year":"2023","unstructured":"Suzuki A. Multidisciplinary approach to management of osteoporosis with osteoporosis liaison service (OLS). Endocr J. 2023;70(5):459\u201364.","journal-title":"Endocr J"},{"issue":"5","key":"841_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1536\/ihj.46.855","volume":"46","author":"H Yasunaga","year":"2005","unstructured":"Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese diagnosis procedure combination-based payment system on cardiovascular medicine-related costs. Int Heart J. 2005;46(5):855\u201366.","journal-title":"Int Heart J"},{"issue":"2-3","key":"841_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.healthpol.2012.01.002","volume":"107","author":"H Hamada","year":"2012","unstructured":"Hamada H, Sekimoto M, Imanaka Y. Effects of the per diem prospective payment system with DRG-like grouping system (DPC\/PDPS) on resource usage and healthcare quality in Japan. Health Policy. 2012;107(2\u20133):194\u2013201. https:\/\/doi.org\/10.1016\/j.healthpol.2012.01.002.","journal-title":"Health Policy"},{"key":"841_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07721-9","author":"Y Takegami","year":"2025","unstructured":"Takegami Y, Imaizumi T, Sato K, et al. Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis. Osteoporos Int. 2025. https:\/\/doi.org\/10.1007\/s00198-025-07721-9.","journal-title":"Osteoporos Int"},{"key":"841_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022;9:175\u201387. https:\/\/doi.org\/10.1007\/s40801-022-00296-5.","journal-title":"Drugs Real World Outcomes"},{"issue":"12","key":"841_CR21","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00198-022-06473-0","volume":"33","author":"RMY Wong","year":"2022","unstructured":"Wong RMY, Wong PY, Liu C, et al. The imminent risk of a fracture\u2014existing worldwide data: a systematic review and meta-analysis. Osteoporos Int. 2022;33(12):2453\u201366.","journal-title":"Osteoporos Int"},{"key":"841_CR22","unstructured":"Committee for the Development of Guidelines for the Prevention and Treatment of Osteoporosis; Japanese Osteoporosis Society; Japanese Society for Bone and Mineral Research; Japan Osteoporosis Foundation. Guidelines for the Prevention and Treatment of Osteoporosis, 2025 Edition. Tokyo: Life Science; 2025. [in Japanese]."},{"issue":"1","key":"841_CR23","first-page":"348","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348\u201355.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"841_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/ije\/dyaa148","volume":"50","author":"H Xiao","year":"2021","unstructured":"Xiao H, Augusto O, Wagenaar BH. Reflection on modern methods: a common error in the segmented regression parameterization of interrupted time-series analyses. Int J Epidemiol. 2021;50(3):1011\u20135.","journal-title":"Int J Epidemiol"},{"key":"841_CR25","unstructured":"Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects. 2021 Mar 23. https:\/\/www.mhlw.go.jp\/content\/001077424.pdf. Accessed 18 Dec 2025."},{"issue":"1","key":"841_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee, International Society of Pharmacoepidemiology","year":"2016","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP): guidelines for good pharmacoepidemiology practice. Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"841_CR27","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1007\/s00198-017-4153-6","volume":"28","author":"S Williamson","year":"2017","unstructured":"Williamson S, Landeiro F, McConnell T, et al. Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporos Int. 2017;28:2791\u2013800.","journal-title":"Osteoporos Int"},{"key":"841_CR28","unstructured":"Japan Osteoporosis Society and Fragility Fracture Network Japan. 2020. http:\/\/www.josteo.com\/ja\/news\/doc\/200518_3.pdf. Accessed 18 Dec 2025."},{"key":"841_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07269-0","author":"G Gondo","year":"2024","unstructured":"Gondo G, Shin J-H, Kunisawa S, Imanaka Y. Impact of the Guidance on Fracture Liaison Services and the Introduction of a New Fee for Secondary Fracture Prevention in Japan: implementation of Secondary Fracture Prevention during hospitalization for fragility fractures. Osteoporos Int. 2024. https:\/\/doi.org\/10.1007\/s00198-024-07269-0.","journal-title":"Osteoporos Int"},{"issue":"10","key":"841_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res. 2024;39(10):1393\u2013405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119.","journal-title":"J Bone Miner Res"},{"key":"841_CR31","doi-asserted-by":"publisher","unstructured":"Kittithamvongs P. Prescription of anti-osteoporosis medication among orthopedic surgeon (PAM-OS study) in osteoporotic hip fracture. Thesis, Chulalongkorn University; 2023 https:\/\/doi.org\/10.58837\/chula.the.2018.279.","DOI":"10.58837\/chula.the.2018.279"},{"key":"841_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-019-0616-z","volume":"14","author":"P Kittithamvongs","year":"2019","unstructured":"Kittithamvongs P, Pongpirul K. Prescription practices of anti-osteoporosis medication among Thai orthopedic surgeons (PAMOS study) in osteoporotic hip fracture. Arch Osteoporos. 2019;14:1\u20136. https:\/\/doi.org\/10.1007\/s11657-019-0616-z.","journal-title":"Arch Osteoporos"},{"key":"841_CR33","unstructured":"Goto Y. Evaluation of health economics in oncology drug therapy. Gan to Kagaku Ryoho. Cancer Chemother. 2024;51(8):791\u2013794."},{"key":"841_CR34","doi-asserted-by":"publisher","unstructured":"Leder BZ. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus. 2018;2(2):62\u201368. https:\/\/doi.org\/10.1002\/jbm4.10041.","DOI":"10.1002\/jbm4.10041"},{"key":"841_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00198-022-06298-x","volume":"33","author":"D Gonz\u00e1lez-Quevedo","year":"2022","unstructured":"Gonz\u00e1lez-Quevedo D, P\u00e9rez-Del-R\u00edo V, Moriel-Garceso D, et al. A 2-year follow-up of a novel fracture liaison service: can we reduce the mortality in elderly hip fracture patients? A prospective cohort study. Osteoporos Int. 2022;33:1695\u2013702. https:\/\/doi.org\/10.1007\/s00198-022-06298-x.","journal-title":"Osteoporos Int"},{"key":"841_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-020-00751-2","volume":"15","author":"L Beaupre","year":"2020","unstructured":"Beaupre L, Moradi F, Khong H, et al. Implementation of an in-patient hip fracture liaison services to improve initiation of osteoporosis medication use within 1-year of hip fracture: a population-based time series analysis using the RE-AIM framework. Arch Osteopor. 2020;15:1\u201310. https:\/\/doi.org\/10.1007\/s11657-020-00751-2.","journal-title":"Arch Osteopor"},{"key":"841_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2023.06.025","author":"C Huang","year":"2023","unstructured":"Huang C, Lin S, Chen H, et al. Osteoporosis care after hip fracture: observation from national health insurance database and fracture liaison services. J Formos Med Assoc. 2023. https:\/\/doi.org\/10.1016\/j.jfma.2023.06.025.","journal-title":"J Formos Med Assoc"},{"key":"841_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-024-02761-3","author":"D Gonz\u00e1lez-Quevedo","year":"2024","unstructured":"Gonz\u00e1lez-Quevedo D, Rubia-Ortega C, S\u00e1nchez-Delgado A, et al. Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients. Aging Clin Exp Res. 2024. https:\/\/doi.org\/10.1007\/s40520-024-02761-3.","journal-title":"Aging Clin Exp Res"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00841-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:38Z","timestamp":1779525998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00841-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00841-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Saeko Fujiwara has received lecture fees from Asahi Kasei Pharma Corporation, Teijin Parma LTD, UCB Japan Co., Ltd., and supervision fees from Amgen K.K. and GE Healthcare Japan, and Medical Data Card, Inc. Hiroshi Hagino has received lecture fees outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. Satoshi Soen has received consulting fees, speaking fees, and\/or honoraria from Alexion Pharma LLC., Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Noriaki Yamamoto has received lecture fees from Amgen K.K., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Teijin Pharma Ltd., UCB Japan Co., Ltd. Akiho Terasawa is an employee of UCB. Izumi Mishiro is an employee of UCB. Jen Timoshanko is an employee and stockholder of UCB. Ryuta Saito is an employee of UCB. Takeshi Sawaguchi and Takashi Matsushita declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Japanese \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects.\u201d Studies using only de-identified secondary data without direct patient involvement are exempt from institutional review board approval [\n                      \n                      ]. Data were obtained under contract and with permission from the Medical Data Vision (MDV) database. Further details are provided in the Materials and Methods section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}